Company Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr.
Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr.
Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences.
The company was founded in 1781 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1781 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 49,281 |
| CEO | Christophe Weber |
Contact Details
Address: 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo, 103-8668 Japan | |
| Phone | 81 3 3278-2111 |
| Website | takeda.com |
Stock Details
| Ticker Symbol | TAK |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| CIK Code | 0001395064 |
| CUSIP Number | 874060205 |
| ISIN Number | US8740602052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christophe Weber | President, Chief Executive Officer and Representative Director |
| Ramona Sequeira | President of Global Portfolio Division |
| Dr. Christopher J. Morabito M.D. | Head of Research & Development Pipeline Strategy |
| Julie Kim | President of the U.S. Business Unit and U.S. Country Head |
| Teresa Marie Bitetti M.B.A. | President of the Global Oncology |
| Dr. Chris Arendt | Head of Oncology Drug Discovery Unit |
| Sheelagh Cawley-Knopf | Head, Research & Development Global Portfolio Strategy |
| Dr. Mahender Nayak | Area Head of ICMEA |
| Takako Ohyabu | Chief Global Corporate Affairs and Sustainability Officer |
| Dion Warren | Vice President and Head of U.S. Oncology Business Unit |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2025 | 424B2 | Prospectus |
| Jun 27, 2025 | FWP | Free Writing Prospectus |
| Jun 26, 2025 | 424B5 | Filing |
| Jun 25, 2025 | F-3ASR | Filing |
| Jun 25, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jun 25, 2025 | 6-K | Report of foreign issuer |
| Jun 25, 2025 | 6-K | Report of foreign issuer |
| Jun 12, 2025 | 6-K | Report of foreign issuer |
| Jun 10, 2025 | 6-K | Report of foreign issuer |
| Jun 6, 2025 | 6-K | Report of foreign issuer |